Evolus Inc
Research Evolus Inc (EOLS) on Bullrun: market cap USD 592.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEOLS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 592.47M
- Financial periodQ2 2026
- RevenueUSD 84.08M
- Net income-USD 8.05M
- Free cash flow-USD 4.09M
- Gross margin68.0%
Valuation Snapshot
latest market cap is USD 592.47M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 297.18M | -USD 51.64M | -USD 45.71M | 66.3% | -0.8 | USD 53.83M | USD 146.10M | -USD 23.11M |
| FY2024 | USD 266.27M | -USD 50.42M | -USD 19.47M | 68.5% | -0.81 | USD 86.95M | USD 121.51M | USD 5.52M |
| FY2023 | USD 202.09M | -USD 61.69M | -USD 34.48M | 68.1% | -1.08 | USD 62.84M | USD 120.36M | -USD 20.69M |
| FY2022 | USD 148.62M | -USD 74.41M | -USD 86.53M | 60.4% | -1.33 | USD 53.92M | USD 71.88M | USD 18.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 592.47M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 432.30M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 701.01M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 608.22M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 422.41M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 361.81M | n/a | n/a | n/a |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Evolus Inc's market cap?
Evolus Inc's market capitalization is USD 592.47M.
What does Evolus Inc do?
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.